Serology study of healthcare workers following a hospital-based outbreak of COVID-19 in North West Tasmania, Australia, 2020.

Introduction Healthcare facilities are high-risk settings for coronavirus disease 2019 (COVID-19) transmission. Early in the COVID-19 pandemic, the first large healthcare-associated outbreak within Australia occurred in Tasmania. Several operational research studies were conducted amongst workers from the implicated hospital campus, to learn more about COVID-19 transmission. Methods Healthcare workers (HCWs) from the implicated hospital campus were invited to complete an online survey and participate in a serology study. Blood samples for serological testing were collected at approximately 12 weeks (round one) and eight months (round two) after the outbreak. A descriptive analysis was conducted of participant characteristics, serology results, and longevity of antibodies. Results There were 261 HCWs in round one, of whom 44 (17%) were polymerase chain reaction (PCR) confirmed outbreak cases; 129 of the 261 (49%) participated in round two, of whom 34 (27%) were outbreak cases. The prevalence of positive antibodies at round one was 15% (n = 38) and at round two was 12% (n = 15). There were 15 participants (12%) who were seropositive in both rounds, with a further 9% (n = 12) of round two participants having equivocal results after previously being seropositive. Six HCWs not identified as cases during the outbreak were seropositive in round one, with three still seropositive in round two. Of those who participated in both rounds, 68% (n = 88) were seronegative at both time points. Discussion Our findings demonstrate that serological testing after this large healthcare-associated COVID-19 outbreak complemented the findings of earlier diagnostic testing, with evidence of additional infections to those diagnosed when use of PCR testing had been restricted. The results also provide evidence of persisting SARS-CoV-2 antibody response eight months after an outbreak in an unvaccinated population. The high proportion of HCWs who remained seronegative is consistent with low community transmission in Tasmania after this outbreak.

[1]  L. Ceretta,et al.  A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19 , 2022, Journal of Clinical Virology.

[2]  J. Carlin,et al.  Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey , 2022, Open forum infectious diseases.

[3]  N. French,et al.  The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review , 2021, PloS one.

[4]  Kylie Smith,et al.  Lessons learnt from the first large outbreak of COVID-19 in health-care settings in Tasmania, Australia , 2021, Western Pacific surveillance and response journal : WPSAR.

[5]  T. Seemann,et al.  COVID-19: Integrating genomic and epidemiological data to inform public health interventions and policy in Tasmania, Australia , 2021, Western Pacific surveillance and response journal : WPSAR.

[6]  M. Gönen,et al.  The seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of vaccination: a systematic review and meta-analysis , 2021, Clinical Microbiology and Infection.

[7]  Y. Kawaoka,et al.  Antibody titers against SARS-CoV-2 decline, but do not disappear for several months , 2021, EClinicalMedicine.

[8]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[9]  R. Tibshirani,et al.  Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome , 2020, Science Immunology.

[10]  P. Galanis,et al.  Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis , 2020, Journal of Hospital Infection.

[11]  P. Escribano,et al.  Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19 , 2020, Scientific Reports.

[12]  M. Nussenzweig,et al.  Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[13]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[14]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[15]  M. Shariff,et al.  SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: A cross-sectional analysis during the COVID-19 pandemic , 2020, International Journal of Infectious Diseases.

[16]  P. G. Choe,et al.  Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection , 2020, Emerging infectious diseases.

[17]  G. Rodger,et al.  Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.

[18]  M. Jorge Cardoso,et al.  Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study , 2020, The Lancet Public Health.

[19]  H. Goossens,et al.  Monitoring approaches for health-care workers during the COVID-19 pandemic , 2020, The Lancet Infectious Diseases.

[20]  Devy M. Emperador,et al.  Antibody tests for identification of current and past infection with SARS‐CoV‐2 , 2020, The Cochrane database of systematic reviews.

[21]  Y. Pan,et al.  Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients , 2020, Clinical Infectious Diseases.

[22]  Andrea Benedetti,et al.  Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis , 2020, BMJ.